The Complementary Duo for prompt Ulcer Healing
D E S C R I P T I O N / M O D E O F A C T I O N
Pantoprazole is a pyridyl methylsulfinyl benzimidazole, which causes irreversible inhibition of proton pump (H+ K+ -AT Pase) function. Pantoprazole after absorption from the upper intestine enters the blood stream. From here it enters the parietal cell, crosses the cell membrane and gets concentrated in the canaliculi. In the canaliculi, because of the strong acidic condition it gets converted to sulphenamide derivatives. The sulphinamide derivatives of pantoprazole inactivate the sulfhydryl group of H+ K+ Adenosine Tri-Phosphatase ( A T Pase), which in turn catalyses the final step of the gastric acid secretion pathway, thus inhibiting both centrally and peripherally mediated gastric acid secretion. It is rapidly activated under strongly acidic conditions. This pH dependent activation profile underlines the in-vitro selectivity of pantoprazole against H+ K+ AT Pase compared with Omeprazole.
Domperidone is a dopamine antagonist acts centrally by inhibiting dopamine receptors at CTZ and peripherally acts on G.I. tract, by increasing Lower Esophageal Spincter (LES) pressure by enhancing gastric contractions and relaxing the pyloric sphincter pressure. It blocks oesophageal reflux by ensuring prompt prokinesis and increasing LES pressure
C O M P O S I T I O N
|
I N D I C AT I O N S
|
D O S A G E
It is given orally in a dose of one capsule once daily about half an hour before breakfast. Pantoprazole is not recommended for children less than 12years. Caution should be exercised in patients with history of liver disease, any other gastrointestinal disorders, any allergy and during pregnancy. Avoid prolonged usage of this medication. It may cause dizziness, do not drive a car or operate machinery while taking this medication. Domperidone products are now contraindicated in patients with severe hepatic impairment, conditions where the cardiac conduction intervals are impaired or could be affected and underlying cardiac diseases as congestive heart failure, when co-administered with QT-prolonging drugs or potent CYP3A4 inhibitors.
S I D E E F F E C T S
Pantoprazole: Headache (>4%), Abdominal pain (4%), Facial edema (<4%), Generalized edema (<2%), Chest pain (4%), Diarrhea (4%), Constipation (<4%), Pruritus (4%), Rash (4%), Flatulence (<4%), Hyperglycemia (1%), Nausea (1%), Vomiting (>4%), Photosensitivity (<2%)
Domperidone: Usually peripheral dopaminergic side effects like dry mouth, diarrhoea and very rearely galactorrhoea and gynaecomastia have been observed. Recent review identified a small increased risk of serious cardiac adverse drug reactions related to the use of domperidone. especially in patients older than 60 years, those taking daily doses of more than 30 mg, and those taking QT-prolonging drugs or CYP3A4 inhibitors concomitantly.
P R E S E N TAT I O N & PACK
Toprazol D capsules are available in blister pack of 10 x 10’s.
